BRENDA - Enzyme Database show
show all sequences of 2.6.1.76

Identification and analysis of a gene encoding L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase involved in the 1,3-diaminopropane production pathway in Acinetobacter baumannii

Ikai, H.; Yamamoto, S.; J. Bacteriol. 179, 5118-5125 (1997)

Data extracted from this reference:

Application
Application
Commentary
Organism
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter baumannii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter calcoaceticus
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter genospecies
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter haemolyticus
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter johnsonii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter junii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter lwoffii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter radioresistens
Cloned(Commentary)
Commentary
Organism
homologs of dat detected by PCR amplification
Acinetobacter calcoaceticus
homologs of dat detected by PCR amplification
Acinetobacter genospecies
homologs of dat detected by PCR amplification
Acinetobacter haemolyticus
homologs of dat detected by PCR amplification
Acinetobacter johnsonii
homologs of dat detected by PCR amplification
Acinetobacter junii
homologs of dat detected by PCR amplification
Acinetobacter lwoffii
homologs of dat detected by PCR amplification
Acinetobacter radioresistens
identification and analysis of the dat gene encoding L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase with Escherichia coli transformants
Acinetobacter baumannii
KM Value [mM]
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
1.46
-
2-oxoglutaric acid
-
Acinetobacter baumannii
4.3
-
L-2,4-diaminobutyric acid
-
Acinetobacter baumannii
Molecular Weight [Da]
Molecular Weight [Da]
Molecular Weight Maximum [Da]
Commentary
Organism
45000
-
4 * 45000, SDS-PAGE
Acinetobacter baumannii
47420
-
deduced from nucleotide sequence
Acinetobacter baumannii
188000
-
native enzyme, gel filtration
Acinetobacter baumannii
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Acinetobacter baumannii
-
-
-
Acinetobacter calcoaceticus
-
-
-
Acinetobacter genospecies
-
3 ATCC 19004
-
Acinetobacter haemolyticus
-
ATCC 17906
-
Acinetobacter johnsonii
-
ATCC 17909
-
Acinetobacter junii
-
ATCC 17908
-
Acinetobacter lwoffii
-
ATCC 15309
-
Acinetobacter radioresistens
-
IAM13186
-
Acinetobacter radioresistens IAM13186
-
IAM13186
-
Purification (Commentary)
Commentary
Organism
recombinant enzyme, overexpressed in Escherichia coli
Acinetobacter baumannii
Reaction
Reaction
Commentary
Organism
L-2,4-diaminobutanoate + 2-oxoglutarate = L-aspartate 4-semialdehyde + L-glutamate
Involved in the formation of 1,3-diaminopropane in Haemophilus influenzae and Acinetobacter baumannii. A product of the ddc gene that also encodes L-2,4-diaminobutyrate decarboxylase in Acinetobacter baumannii. Differs from EC 2.6.1.46 diaminobutyrate-pyruvate transaminase, which has pyruvate as the amino-group acceptor
Acinetobacter baumannii
Substrates and Products (Substrate)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
beta-alanine + 2-oxoglutaric acid
-
288731
Acinetobacter baumannii
?
-
-
-
?
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter calcoaceticus
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter johnsonii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter lwoffii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter baumannii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter genospecies
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter haemolyticus
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter junii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter radioresistens
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter radioresistens IAM13186
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter calcoaceticus
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter johnsonii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter lwoffii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter baumannii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter genospecies
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter haemolyticus
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter junii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter radioresistens
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter radioresistens IAM13186
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-lysine + oxaloacetic acid
-
288731
Acinetobacter baumannii
?
-
-
-
?
L-ornithine + pyruvic acid
-
288731
Acinetobacter baumannii
?
-
-
-
?
Subunits
Subunits
Commentary
Organism
tetramer
4 * 45000, SDS-PAGE
Acinetobacter baumannii
pH Optimum
pH Optimum Minimum
pH Optimum Maximum
Commentary
Organism
8.25
8.75
-
Acinetobacter baumannii
Application (protein specific)
Application
Commentary
Organism
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter baumannii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter calcoaceticus
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter genospecies
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter haemolyticus
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter johnsonii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter junii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter lwoffii
medicine
drug development, Acinetobacter sp. can be part of the normal flora of human skin but also of opportunistic infections like septicemia, pneumonia, endocarditis, meningitis, skin and wound sepsis or urinary tract infections, clinically important isolates show widespread and increasing resistance to many commonly used antibiotics
Acinetobacter radioresistens
Cloned(Commentary) (protein specific)
Commentary
Organism
identification and analysis of the dat gene encoding L-2,4-diaminobutyrate:2-ketoglutarate 4-aminotransferase with Escherichia coli transformants
Acinetobacter baumannii
homologs of dat detected by PCR amplification
Acinetobacter calcoaceticus
homologs of dat detected by PCR amplification
Acinetobacter genospecies
homologs of dat detected by PCR amplification
Acinetobacter haemolyticus
homologs of dat detected by PCR amplification
Acinetobacter johnsonii
homologs of dat detected by PCR amplification
Acinetobacter junii
homologs of dat detected by PCR amplification
Acinetobacter lwoffii
homologs of dat detected by PCR amplification
Acinetobacter radioresistens
KM Value [mM] (protein specific)
KM Value [mM]
KM Value Maximum [mM]
Substrate
Commentary
Organism
Structure
1.46
-
2-oxoglutaric acid
-
Acinetobacter baumannii
4.3
-
L-2,4-diaminobutyric acid
-
Acinetobacter baumannii
Molecular Weight [Da] (protein specific)
Molecular Weight [Da]
Molecular Weight Maximum [Da]
Commentary
Organism
45000
-
4 * 45000, SDS-PAGE
Acinetobacter baumannii
47420
-
deduced from nucleotide sequence
Acinetobacter baumannii
188000
-
native enzyme, gel filtration
Acinetobacter baumannii
Purification (Commentary) (protein specific)
Commentary
Organism
recombinant enzyme, overexpressed in Escherichia coli
Acinetobacter baumannii
Substrates and Products (Substrate) (protein specific)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
beta-alanine + 2-oxoglutaric acid
-
288731
Acinetobacter baumannii
?
-
-
-
?
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter calcoaceticus
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter johnsonii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter lwoffii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter baumannii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter genospecies
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter haemolyticus
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter junii
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter radioresistens
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
288731
Acinetobacter radioresistens IAM13186
L-glutamic acid + L-aspartic beta-semialdehyde
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter calcoaceticus
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter johnsonii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter lwoffii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter baumannii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter genospecies
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter haemolyticus
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter junii
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter radioresistens
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-glutamic acid + L-aspartic beta-semialdehyde
-
288731
Acinetobacter radioresistens IAM13186
L-2,4-diaminobutyric acid + 2-oxoglutaric acid
-
-
-
r
L-lysine + oxaloacetic acid
-
288731
Acinetobacter baumannii
?
-
-
-
?
L-ornithine + pyruvic acid
-
288731
Acinetobacter baumannii
?
-
-
-
?
Subunits (protein specific)
Subunits
Commentary
Organism
tetramer
4 * 45000, SDS-PAGE
Acinetobacter baumannii
pH Optimum (protein specific)
pH Optimum Minimum
pH Optimum Maximum
Commentary
Organism
8.25
8.75
-
Acinetobacter baumannii
Other publictions for EC 2.6.1.76
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [°C]
Temperature Range [°C]
Temperature Stability [°C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [°C] (protein specific)
Temperature Range [°C] (protein specific)
Temperature Stability [°C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
738983
Chen
Design of an ectoine-responsiv ...
Halomonas elongata, Halomonas elongata DSM 2581
Metab. Eng.
30
149-155
2015
-
1
-
-
4
-
-
6
-
-
-
-
-
2
-
-
-
-
-
-
-
-
2
-
-
-
-
6
-
-
-
-
-
-
-
-
1
-
-
-
4
-
-
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
6
-
-
-
-
-
-
-
-
6
6
640091
Ono
Characterization of biosynthet ...
Halomonas elongata
J. Bacteriol.
181
91-99
1999
-
-
-
-
-
-
-
2
-
1
2
-
-
1
-
-
1
-
-
-
1
-
6
1
1
-
-
-
1
-
-
1
-
1
-
-
-
-
1
-
-
-
-
-
-
2
-
1
2
-
-
-
-
1
-
-
1
-
6
1
1
-
-
-
1
-
-
1
-
-
-
-
-
-
288732
Ikai
Two genes involved in the 1,3- ...
Acinetobacter baumannii, Haemophilus influenzae
Biol. Pharm. Bull.
21
170-173
1998
-
2
1
-
-
-
-
-
-
-
2
-
-
6
-
-
-
1
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
2
1
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
288731
Ikai
Identification and analysis of ...
Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter genospecies, Acinetobacter haemolyticus, Acinetobacter johnsonii, Acinetobacter junii, Acinetobacter lwoffii, Acinetobacter radioresistens, Acinetobacter radioresistens IAM13186
J. Bacteriol.
179
5118-5125
1997
-
8
8
-
-
-
-
2
-
-
3
-
-
12
-
-
1
1
-
-
-
-
21
1
-
-
-
-
1
-
-
-
-
-
-
-
8
8
-
-
-
-
-
-
-
2
-
-
3
-
-
-
-
1
-
-
-
-
21
1
-
-
-
-
1
-
-
-
-
-
-
-
-
-